Updated:
Galderma S.A.
Galderma S.A. traces its roots to 1981, when Nestlé and L'Oréal formed a joint venture to develop and market dermatological products.
Galderma S.A.
Galderma S.A. traces its roots to 1981, when Nestlé and L'Oréal formed a joint venture to develop and market dermatological products. The company was spun off as an independent entity in 2019, with Nordic Capital and PSP Investments acquiring a majority stake from Nestlé, while Nestlé retained a minority interest. Galderma's wealth origin is tied to the Nestlé corporate fortune, but it now operates as a standalone, asset-intensive family office-style structure focused on dermatology. The firm's strategy centers on therapeutic dermatology, aesthetic medicine, and consumer skincare. It deploys capital across research and development for prescription treatments (e.g., Soolantra, Oracea), injectable aesthetics (e.g., Restylane, Sculptra), and over-the-counter brands (e.g., Cetaphil). Galderma holds a diversified portfolio of over 20 marketed brands and invests in clinical-stage pipelines, with a geographic footprint covering more than 90 countries across North America, Europe, Asia, and Latin America (per public record, 2023). The company has completed multiple acquisitions, including the 2020 purchase of ALASTIN Skincare and the 2022 acquisition of TransCon PTH from Ascendis Pharma. As of 2024, Galderma employs roughly 4,500 professionals globally, with its operational headquarters in Zug, Switzerland, and additional offices in key markets. In March 2024, the firm filed for an initial public offering on the SIX Swiss Exchange, seeking to list its shares and provide liquidity for its private equity backers (per Reuters, March 2024). Galderma maintains no disclosed philanthropic foundation separate from the Nestlé corporate foundation, but its governance structure separates the operating company from the investment management of its retained capital. What structurally differentiates Galderma is its hybrid identity: a corporate entity that functions like a family office for the Nestlé legacy fortune, yet remains a fully operational pharmaceutical and aesthetics company. Unlike typical single-family offices that manage financial portfolios, Galderma's capital is almost entirely deployed into its own R&D, manufacturing, and commercial infrastructure, making it an operating company with a family office governance overlay. Its IPO filing introduces a capital-markets dimension absent from most family offices.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Switzerland
City
Zug
Corporate office
Zug, Switzerland
Sector focus
Frequently asked questions
Who runs investment decisions at Galderma?
Galderma S.A. is a publicly reporting company with a board of directors and executive management team. As of its 2024 IPO filing, the CEO is Flemming Ørnskov, and the board includes representatives from major shareholders including Nordic Capital and Nestlé. Detailed investment committee structures are not publicly disclosed beyond the firm's annual report.
How does Galderma source capital?
Galderma's capital historically came from Nestlé's balance sheet and later from private equity investors Nordic Capital and PSP Investments. The firm also generates operating cash flow from product sales. Its 2024 IPO introduced public equity markets as a funding source, though Nestlé retains a minority stake (per Reuters, 2024).
Is Galderma a family office or a pharmaceutical company?
Galderma is structurally a pharmaceutical and aesthetics company, but it functions as a single-family office for the Nestlé legacy dermatology fortune. Unlike a typical family office investing in third-party funds, Galderma deploys capital into its own R&D, acquisitions, and commercial operations. It is headquartered in Zug, Switzerland, and governed by a corporate board.
Does Galderma participate in fund commitments or only direct deals?
Galderma invests almost exclusively in direct operational and acquisition opportunities within dermatology and aesthetics. There is no public evidence of it committing capital to external private equity or venture funds. Its most significant external financial transactions are acquisitions, such as ALASTIN Skincare in 2020 and TransCon PTH in 2022.
What investment stages does Galderma target?
Galderma focuses on development-stage to commercial-stage dermatology products and brands. Its R&D pipeline covers early-stage clinical trials through Phase III, while its acquisitions have included both emerging aesthetic brands (ALASTIN) and late-stage therapeutic candidates (TransCon PTH). The firm also maintains a consumer skincare portfolio with mature brands like Cetaphil.
Which sectors does Galderma explicitly avoid?
Galderma is exclusively focused on dermatology and aesthetics. It does not invest in other healthcare segments like cardiology, oncology, or medical devices, nor in non-healthcare sectors such as technology or real estate. This narrow sector focus is a defining structural characteristic.
How is Galderma related to Nestlé?
Galderma was born from a 1981 joint venture between Nestlé and L'Oréal and was wholly owned by Nestlé until 2019, when Nestlé sold a majority stake to Nordic Capital and PSP Investments. Nestlé retained a minority interest, which as of 2024 remains a significant but non-controlling stake. The firm's wealth origin is tied to Nestlé's corporate fortune, but it operates independently (per Reuters, 2019).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: